Impact News +++ Hive Digital expands BUZZ HPC with new cluster in Quebec, acquires Toronto facility to fuel growth (Proactive Investors) +++ HIVE DIGITAL Aktie -3,44%

AB SCIENCE Aktie

>AB SCIENCE Aktienkurs

1.34 EUR +0.5% (Tradegate)

Ask: 1.348 EUR / 741 Stück

Bid: 1.33 EUR / 753 Stück

Tagesumsatz: 2599 Stück

Realtime Kurs von 8 bis 22 Uhr!

AB SCIENCE Aktie über LYNX handeln

Intraday

1 Jahr

>AB SCIENCE Performance

1 Woche: +15,5%

1 Monat: +4,7%

3 Monate: -3,5%

6 Monate: +51,2%

1 Jahr: +12,8%

laufendes Jahr: +49,6%

>AB SCIENCE Aktie

Name:

AB SCIENCE S.A. EO-,01

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0010557264 / A1CXBG

Symbol/ Ticker:

A8D (Frankfurt)

Kürzel:

FRA:A8D, ETR:A8D, A8D:GR

Index:

Webseite:

https://www.ab-science.co..

Marktkapitalisierung:

77.43 Mio. EUR

Umsatz:

1.07 Mio. EUR

EBITDA:

-5.69 Mio. EUR

Gewinn je Aktie:

-0.15 EUR

Schulden:

18.47 Mio. EUR

Liquide Mittel:

7.99 Mio. EUR

Umsatz-/ Gewinnwachstum:

-1.9% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

80.93 / - / -

Gewinnm./ Eigenkapitalr.:

- / -

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

AB SCIENCE

Letzte Datenerhebung:

24.06.25

>AB SCIENCE Eigentümer

Aktien: 66.18 Mio. St.

f.h. Aktien: 22.73 Mio. St.

Insider Eigner: 34.34%

Instit. Eigner: 0.15%

Leerverk. Aktien: -

>AB SCIENCE Peer Group

ABIONYX

ADOCIA

CARMAT

CLARIANE

CROSSJECT

EUROAPI

KLEA HOLDING

MAUNA KEA

SARTORIUS STEDIM

SENSORION

>AB SCIENCE Chart & Kurs - Tradegate

>AB SCIENCE News

23.06.25 - 09:36	AB Science: New Peer-Reviewed Masitinib Trial Shows Strong Evidence Supporting Potential To Treat AD (AFX)
	PARIS (dpa-AFX) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that a new peer-reviewed data provide strong evidence supporting Masitinib's potential for the treatment o......

23.06.25 - 08:06	AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer′s disease (GlobeNewswire EN)
	PRESS RELEASE...

09.06.25 - 08:48	AB Science: EMA Approves Shelf-Life Extension For MASIVET To 48 Months (AFX)
	PARIS (dpa-AFX) - AB Science (ABSCF.PK) announced that the European Medicines Agency (EMA) has approved an extension of the shelf life of its veterinary medicine, MASIVET, to 48 months from 36 mon......

09.06.25 - 08:03	AB Science announces EMA approval of Masivet shelf-life extension to 4 years (GlobeNewswire EN)
	PRESS RELEASE...

23.05.25 - 07:54	AB Science announces the settlement delivery of its latest capital increase for €1.8 million (GlobeNewswire EN)
	PRESS RELEASE...

20.05.25 - 07:54	AB Science announces the successful completion of a EUR 1.8 million private placement (GlobeNewswire EN)
	PRESS RELEASE...

19.05.25 - 10:01	AB Science Receives Chinese Patent Protecting Masitinib To Treat Covid-19 Until 2041; Stock Up (AFX)
	BEIJING (dpa-AFX) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that it has received Chinese patent protecting Masitinib in the treatment of Covid-19 until April 2041.I......

19.05.25 - 07:54	AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection (GlobeNewswire EN)
	PRESS RELEASE...

15.05.25 - 08:09	AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib (GlobeNewswire EN)
	PRESS RELEASE...

12.05.25 - 09:42	AB Science Posts Narrower Loss In FY24 (AFX)
	BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AB Science SA (ABSCF.PK) posted a fiscal 2024 net loss of 7.8 millon euros compared to a loss of 12.0 million euros, prior year. Basic loss per share was 0.15 ......

12.05.25 - 08:18	AB Science reports its revenues for the year 2024 and provides an update on its activities (GlobeNewswire EN)
	PRESS RELEASE...

05.05.25 - 18:06	AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting (GlobeNewswire EN)
	PRESS RELEASE...

01.05.25 - 10:09	AB Science will publish its 2024 annual financial report on May 9, 2025 (GlobeNewswire EN)
	PRESS RELEASE...

23.04.25 - 19:03	AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (GlobeNewswire EN)
	PRESS RELEASE...

14.04.25 - 18:06	AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease (GlobeNewswire EN)
	PRESS RELEASE...

04.03.25 - 08:39	AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch (GlobeNewswire EN)
	PRESS RELEASE...

29.01.25 - 19:06	AB Science today provides an update on its masitinib platform (GlobeNewswire EN)
	PRESS RELEASE...

24.01.25 - 18:03	AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET (GlobeNewswire EN)
	PRESS RELEASE...

22.01.25 - 19:03	AB Science will participate in the Biomed Forum investors conference (GlobeNewswire EN)
	PRESS RELEASE...

17.12.24 - 19:06	AB Science provides a summary of the webcast held on December 16, 2024 (GlobeNewswire EN)
	PRESS RELEASE...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram